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Abstract
Background: In spite of recent advances in diagnostic and therapeutic measures, the prognosis of hepatocellular
carcinoma (HCC) patients remains poor. Therefore, it is crucial to understand what factors are involved in
promoting development of HCC. Evidence is accumulating that members of the chemokine receptor family are
viewed as promising therapeutic targets in the fight against cancer. More recent studies have revealed that
chemokine receptor CXCR7 plays an important role in cancer development. However, little is known about the
effect of CXCR7 on the process of HCC cell invasion and angiogenesis. The aim of this study is to investigate the
expression of CXCR7 in hepatocellular carcinoma tissues and cell lines and to evaluate the role of CXCR7 in tumor
growth, angiogenesis and invasion of HCC cells.
Methods: We constructed CXCR7 expressing shRNA, and CXCR7shRNA was subsequently stably transfected into human
HCC cells. We evaluated the effect of CXCR7 inhibition on cell invasion, adhesion, VEGF secretion, tube formation and
tumor growth. Immunohistochemistry was done to assess the expression of CXCR7 in human hepatocellular carcinoma
tissues and CD31 in tumor of mice. We also evaluated the effect of VEGF stimulation on expression of CXCR7.
Results: CXCR7 was overexpressed in hepatocellular carcinoma tissues. We showed that high invasive potential
HCC cell lines express high levels of CXCR7. In vitro, CXCL12 was found to induce invasion, adhesion, tube
formation, and VEGF secretion in SMMC-7721 cells. These biological effects were inhibited by silencing of CXCR7 in
SMMC-7721 cells. In addition, we also found that VEGF stimulation can up-regulate CXCR7 expression in SMMC-
7721 cells and HUVECs. More importantly, enhanced expression of CXCR7 by VEGF was founctional. In vivo, tumor
growth and angiogenesis were suppressed by knockdown of CXCR7 in SMMC-7721 cells. However, silencing of
CXCR7 did not affect metastasis of tumor in vivo.
Conclusions: Increased CXCR7 expression was found in hepatocellular carcinoma tissues. Knockdown of CXCR7
expression by transfected with CXCR7shRNA significantly inhibits SMMC-7721 cells invasion, adhesion and
angiogenesis. Finally, down-regulation of CXCR7 expression lead to a reduction of tumor growth in a xenograft
model of HCC. This study provides new insights into the significance of CXCR7 in invasion and angiogenesis of HCC.
Background
HCC is one of the common types of cancers worldwide
and the incidence of HCC is increasing. Understanding
the molecular mechanisms that control HCC provides
the foundation for therapeutic intervention. Invasion,
angiogenesis and metastasis is a typical process of HCC
progression. The process of HCC invasion and
metastasis is a multistep event that involves cell migra-
tion, local invasion, angiogenesis and growth at a sec-
ondary site [1,2]. Angiogenesis plays an important role
in tumor progression and the development of metas-
tases, and may be proved to be a useful prognostic bio-
marker for HCC. Controlling the invasion and
angiogenesis of cancer remains a crucial goal for the
successful treatment of HCC. The lack of effective
therapies for HCC is related to poor understanding of
the molecular mechanisms underlying cancer invasion
and metastasis. Thus, elucidation of molecular
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for the malignant potential of HCC are urgently needed.
There is abundant evidence to show that chemokine
CXCL12 and its receptors (CXCR4, CXCR7) are
involved in progression of tumors [3,4].
Stromal cell-derived factor-1 (SDF-1, also called
CXCL12) is a member of the CXC subfamily of che-
mokines and express in a variety of tissues including
lung, liver, bone marrow and lymph nodes [5-7].
CXCL12 elicits biologic function through binding to
its receptor, CXCR4, which is present on the cell sur-
face and is a seven-transmembrane span G-protein-
coupled receptor [8]. CXCL12 plays a role in a number
of important physiological processes including leuko-
cyte trafficking and vasculogenesis [6,9]. More impor-
tantly, CXCL12 plays a crucial role in the process of
invasion and metastasis of tumor cells [3]. CXCL12 sti-
mulates proliferation, dissociation, migration, and inva-
sion in a wide variety of tumor cells, including breast
cancer cells, pancreatic cancer cells and HCC cells
[3,10,11].
CXCR4 belongs to the large superfamily of G protein-
coupled receptors and plays an important role in a vari-
ety of normal cellular processes, such as vascularization,
nervous systems development and haematopoiesis
[12,13]. Numerous studies have demonstrated that
CXCR4 frequently overexpressed in a variety of human
tumors, such as breast cancer, prostate cancer and hepa-
tocellular carcinoma [3,14,15]. It has been shown that
the overexpression of CXCR4 significantly correlate with
metastasis and poor prognosis in different tumor types
[16,17]. In addition, inhibition of CXCR4 function by
the administration of AMD3100, CXCR4-specific pep-
tide antagonist, can dramatically impair tumor forma-
tion and metastasis [18]. Until recently, CXCR4 was
considered to be the only receptor for CXCL12. How-
ever, a recent study has shown that chemokine receptor
CXCR7 can also bind to CXCL12, and it is identified as
a second receptor for CXCL12 [19].
Recently, a newly discovered chemokine receptor
called CXCR7 has been identified [19]. CXCR7 med-
iates a broad range of cellular activities, including
proliferation, survival, and adhesion by binding with
CXCL12 [19]. However, the function of CXCR7 is
still unclear and controversial. Some studies suggested
that CXCR7 is a non-signaling decoy receptor and
can not activate intracellular signaling cascades. Gry-
mula et al. [20] found that CXCR7 expressed on
rhabdomyosarcoma cells was a signaling receptor and
could activate (MAPK)p42/44 and AKT phosphoryla-
tion through binding with its ligand. In addition,
CXCR7 participated in regulation of rhabdomyosar-
coma cell motility, directional chemotaxis, expression
of MMPs, and cell adhesion and enhanced in vivo
metastatic potential of rhabdomyosarcoma cells.
Furthermore, CXCR7 as a inclassical chemokine
receptor plays an important role in the CXCL12/
CXCR4-mediated transendothelial migration (TEM)
of human cancer cells [21]. It has been demonstrated
that CXCR7 is expressed in variety of tumor cell lines
and normal cells including activated endothelial cells,
fetal liver cells, T cells, B cells and renal multipotent
progenitors [19,22]. Importantly, overexpression of
CXCR7 has been observed in various tumors, includ-
ing breast cancer, lung cancer, prostate cancer and
pancreatic cancer [4,23-25]. Miao et al.[ 4 ]h a v e
shown that CXCR7 promotes tumor growth in a
mouse model of lung and breast cancers, and that
expression of CXCR7 influences experimental lung
metastasis. In addition, expression of CXCR7
enhances the cell adhesion, invasion, blood vessel
sprout formation in vitro and promotes tumor growth
in vivo [24]. Another study has revealed that CXCR7
mediated proliferation and chemotaxis of tumor cells
towards CXCL12 in vitro, but no effect of CXCR7 on
tumor growth and metastasis was observed in vivo
[ 2 6 ] .T h e s er e s u l t sp r o v i d ear e a s o n a b l eb a s i st op r o -
pose that the CXCL12/CXCR7 interaction could play
an important role in cancer progression. Although the
role of CXCL12 in the promotion of invasive growth
is well documented and the intracellular signals trig-
gered by CXCR4 activation have been extensively
investigated, the role of CXCL12/CXCR7 axis in regu-
lating tumor growth of HCC is not yet known. In
addition, the published evidence is not consistent on
whether CXCR7 expression contributes to tumor
growth, invasion and metastasis. Thus, it is necessary
to further explore the role of CXCR7 in cancer
development.
T h e r ei si n c r e a s i n ge v i d e n c et h a tC X C R 7m a yp a r t i -
cipate in tumor development. In previous study,
CXCR7 was demonstrated to express on a large per-
centage of tumor -associated blood vessels of human
liver HCC [4]. However, the biological significance of
CXCL12/CXCR7 interaction in development of HCC is
unclear. The present study was undertaken to test the
hypothesis that CXCL12/CXCR7 was involved in
malignant properties of HCC. We have studied the
expression of CXCR7 in hepatocellular carcinoma tis-
sues and cell lines. We have also evaluated the effect
of specific inhibition of CXCR7 on CXCL12-induced
cell invasion, adhesion and angiogenesis. In addition,
we have investigated whether VEGF stimulation affects
CXCR7 expression. Finally, we have further analyzed
whether inhibition of CXCR7 expression would affect
tumor growth and metastasis in vivo.
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Patients and tumor specimens
Patients underwent surgical resection at the The First
Affiliated Hospital, Chongqing Medical University
between February 2008 and October 2009. All cases of
hepatocellular carcinoma tissues were diagnosed clini-
cally and pathologically. None of the patients had
received any preoperative treatments (radiotherapy or
chemotherapy). Hepatocellular carcinoma tissues were
embedded with paraffin and stored in Department of
Pathology, Chongqing Medical University, China. Paraf-
fin-embedded hepatocellular carcinoma specimens were
obtained from 35 HCC patients [22 male, 13 female;
average age of 52 years (range, 38-68 years)].
Construction of Small Hairpin RNA plasmid
K n o c k d o w no fC X C R 7w a sa c h i e v e db ye x p r e s s i o no f
short hairpin RNA (shRNA) from the pGPU6/Neo vec-
tor containing the human U6 promoter (GenePharma,
Shanghai, China). All DNA oligonucleotides were
synthesized by Shanghai Sangon Biological Engineering
Technology & Services Co., Ltd. (Shanghai, China). The
sequence of the oligonucleotide targeted to CXCR7 is
5’-GCATCTCTTCGACTACTCAGA -3’, corresponding
to positions 223 to 243 within the CXCR7 mRNA
sequence (accession no. NM_020311). The following
complementary oligonucleotide encoding short hairpin
RNA was designed to knock down CXCR7: (sense)
5’-CAC CGCATCTCTTCGACTACTCAGATTCAAG
AGATCTGAGT AGTCGAAGAGATGCTTTTTTG-3’
and (antisense) 5’-GATCCAAAAAAGCATCTCTT
CGACTACTCAGATCTCTTGAATCTGAGTAGTCG
AAGAGATGC-3’. The pGPU6/Neo plasmid was linear-
ized with BamH I and Bbs I to permit the insertion of the
annealed oligonucleotides. DNA oligonucleotides were
annealed by incubating the mixed oligonucleotides in the
PCR thermocycler using the following profile: 95°C for
5 min, 80°C for 5 min, 75°C for 5 min and gradually
cooled to room temperature. Annealed oligonucleotides
were ligated to the BbsIa n dBamHIs i t e so ft h ep G
PU6/Neo plasmid. The scrambled shRNA was used as a
negative control(referred to as “NC” in the text), of which
the sequence was 5’-GACGAGCTTCTACACAATCAT-3’.
The recombinant constructs were verified by DNA
sequencing and by analyzing the fragments generated
from digestion with BamH I. The efficiency of knockdown
was determined by Western blot and RT-PCR.
Cell lines and cell culture conditions
Human HCC cell lines HepG2, Hep3B, SMMC-7721
and human umbilical vein endothelial cells (HUVECs)
were purchased from Cell Bank of Shanghai Institute of
Biochemistry & Cell Biology, Chinese Academy of
Sciences (Shanghai, China). Human HCC cell lines
MHCC97L, MHCC97H and HCCLM6 were obtained
from Liver Cancer Institute and Zhong Shan Hospital of
Fudan University, Shanghai, China. MHCC97L,
MHCC97H and HCCLM6 were maintained in DMEM
(Gibco, USA) supplemented with 10% heat-inactivated
FBS (HyClone, USA). HepG2, Hep3B and SMMC-7721
were cultured in an RPMI-1640 (Gibco, USA) medium
supplemented with 10% heat-inactivated FBS. HUVECs
was maintained in F12 medium containing 10% FBS
(HyClone, USA). All the media were supplemented with
100 U/ml penicillin and 100 μg/mL streptomycin (Invi-
trogen, USA) and maintained in 5% CO2 at 37°C.
Generation of stable transfectants
SMMC-7721 cells were seeded in six-well plates to 80-
90% confluence. The cells were transfected with mix-
tures of shRNA plasmids and Lipofectamine™ 2000
reagent (Invitrogen, USA) according to the manufac-
turer’s instructions. Forty-eight hours after transfection,
transfected cells were grown in growth medium contain-
ing 0.4 mg/ml G418 (Gibco, USA) for selection. Stable
transfectant clones with low expression of CXCR7 were
evaluated by RT-PCR and Western blot analysis. Stable
transfectants were expanded for subsequent experi-
ments. SMMC-7721 cells transfected by CXCR7shRNA
were referred to as CXCR7shRNA cells, while SMMC-
7721 cells transfected by scrambled shRNA as NC cells.
RNA extraction and reverse transcription PCR
Total RNA in HCC cells was extracted using Trizol
(Invitrogen, USA). RT-PCR was performed using reverse
transcriptase cDNA synthesis kit (Takara, Japan) accord-
ing to the manufacturer’s protocol. One microgram of
total RNA was reversely transcribed into cDNA followed
by PCR amplification using specific primers: CXCR7,
forward (5’-TGGGTGGTCAGTCTCGT-3’)a n dr e v e r s e
(5’-CCGGCAGTAGGTCTCAT-3’); CXCR4, forward
(5’-CCTGAAGTACCCCATCGAGCAC-3’) and reverse
(5’-ATACCCCTCGTAGATGGGCACA-3’), GAPDH,
forward (5’-GAAGGTGAAGGTCGGAGTC-3’)a n d
reverse(5’-GAAGATGGTGATGGGATTTC-3’). CXCR7
was amplified by 30 cycles at 94°C for 40 s, 57°C for 30
s, and 72°C for 1 min in order. CXCR4 was amplified by
30 cycles at 94°C for 35 s, 60°C for 30 s, and 72°C for 1
min in order. Both were followed by a 7 min extension
at 72°C. PCR products were electrophoresed on 1.5%
agarose gel containing ethidium bromide and visualized
by UV-induced fluorescence.
Western blot analysis
For the preparation of lysates, the cells were washed
with ice-cold PBS solution and lysed in lysis buffer
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P-40, and 0.1% SDS supplemented with protease inhibi-
tors). Cells were scraped into microcentrifuge tubes and
centrifuged at 10,000 × g for 15 min at 4°C. The super-
natant was collected, and protein concentrations were
determined with the Bio-Rad protein assay reagent
according to the Bradford method. Samples were sub-
jected to 10% PAGE analysis after they were boiled for
5 min and electrophoretically transferred to polyvinyli-
dene difluoride (PVDF) membranes (Millipore, USA).
Blocking was performed in 5% nonfat dried milk in
Tris-buffered saline containing 0.1% Tween 20 at room
temperature for 1 h. Membranes were then incubated
with primary antibody under constant agitation at anti-
body dilutions suggested by the antibody supplier over-
night at 4°C. After several washings, membranes were
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (anti-rabbit) for 1 h at room tempera-
ture under constant agitation. Proteins were visualized
by using an enhanced chemiluminescence system (ECL;
Amersham Biosciences, USA).
Cell invasion assay
SMMC-7721 cells invasion in response to CXCL12 was
assayed in the Biocoat Matrigel invasion chamber (Bec-
ton Dickinson, USA) with 8-μm porosity polycaronate
filter membrane that was coated with Matrigel. Control,
NC and CXCR7 shRNA transfected cells were sus-
pended at 3 × 10
5 cells/ml in serum-free media respec-
tively, and then 0.2 ml cell suspension was added to the
upper chamber. Next, 0.5 ml serum-free media with var-
ious concentrations of CXCL12 (0, 10 or 100 ng/ml)
was added to the lower chamber. The chambers were
then incubated for 24 h at 37°C with 5% CO2.A f t e r
incubation, noinvasive cells were gently removed from
the top of the Matrigel with a cotton-tipped swab. Inva-
sive cells at the bottom of the Matrigel were fixed in 4%
paraformaldehyde and stained with hematoxylin. The
number of invasive cells was determined by counting
the hematoxylin-stained cells. For quantification, cells
w e r ec o u n t e du n d e ram i c r o s c o p ei nf i v ef i e l d s( u p ,
down, median, left, right. ×200).
Cell adhesion assay
Cell adhesion assay was carried out by using the CytoSe-
lect™ ECM Cell Adhesion Assay kit (Cell BioLabs, USA)
following the instruction manual. Briefly, the 48-well
plate precoated with laminin (LN) or fibronectin (FN)
were washed with PBS twice and blocked for 1 h at
37°C with RPMI 1640 containing 0.1% BSA before plat-
ing cells. Plates were again washed with PBS and air-
dried. SMMC-7721 cells were preincubated with
CXCL12 (100 ng/ml) for 24 h at 37°C. A cell suspension
containing 2 × 10
5 cells/ml was prepared in serum free
media. The cell suspension (150 μl) was added to the
inside of each well (BSA-coated wells were provided as
a negative control). Cells were allowed to attach for 1 h
at 37°C. Subsequently, unattached cells were removed
by gentle washing 3 times with PBS. Then the attached
cells were stained with 1% crystal violet. Each well was
gently washed 3 times with PBS. The total crystal violet
bound to the cells was eluted with 10% acetic acid and
measured by the absorbance at 560 nm. All the experi-
ments were repeated 3 times in duplicate wells.
ELISA for VEGF
SMMC-7721 cells were plated in 24-well tissue culture
plates at a density of 1 × 10
5 cells per well and followed
with serum starvation for 24 h with RPMI-1640. Then,
cells were treated with recombinant human CXCL12
(100 ng/ml)(Peprotech, UK), and the supernatants were
collected 24 h after treatment. VEGF concentration was
determined using Quantikine ELISA kits according to
the manufacturer’s instructions (R&D Systems, Minnea-
polis, MN).
In vitro tube formation coculture assay
To perform the tube formation assay, Transwell cham-
bers were precoated with growth factor-reduced Matri-
gel (200 μLo f1 0m g / m L ) .C o n t r o l ,N Ca n dC X C R 7
shRNA transfected cells were seeded at a density of 2 ×
10
4 cells/well in 24-well plates and cultured for 24 h
respectively. HUVECs (2 × 10
4 cells/well) were then
seeded in Transwell chambers precoated with the Matri-
gel. Subsequently, Transwell chambers containing
HUVECs were inserted into the 24-well plates and
cocultured for 24 h. After 24 h of cocultured at 37°C
and 5% CO2, the number of capillary-like tubes from
three randomly chosen fields was counted and photo-
graphed under an Nikon inverted microscope (Japan).
Immunohistochemistry and quantitation of microvessel
density
Immunohistochemistry was used to analyze the expres-
sion of CXCR7 and CD31. Paraffin-embedded human
hepatocellular carcinoma tissues were sectioned at 5 μm
thickness. Tumors established in nude mice were iso-
lated and fixed in 4% paraformaldehyde, embedded in
paraffin, and cut in 6 μm sections. Tumor sections were
deparaffinized, rehydrated, and quenched with 3%
hydrogen peroxide for 10 min at room temperature.
The sections were incubated in protein blocking solu-
tion (5% normal horse serum, 1% goat serum in PBS)
for 10 min before the addition of the primary antibody.
The sections were incubated for 2 h at 37°C with rat
antimouse CD31 (BD Biosciences, USA) or rabbit anti-
human CXCR7 (Abcam, UK) at 1:100 dilutions. After
incubation, the sections were washed in PBS for 10 min,
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antibody was applied. After washings, the avidin-biotin
complex was then applied to the sections, followed by
extensive washing steps. Diaminobenzidine chromogen
was then added to the sections and incubated in the
dark for 5 min.
MVD in tumor tissues was determined by immunohis-
tochemical staining with an endothelial-specific antibody
CD31. For Quantitative analyses of MVD, three random
high-power fields (×200) were photographed for each
tumor section. MVD was calculated as mean number of
tumor vessels per high-power field.
In vivo tumorigenicity
Male nude mice (BALB/c) of six-week-old were pur-
chased from the Laboratory Animal Center of Chongq-
ing Medical University (Chongqing, China) and bred
under specified pathogen-free conditions. The mice
were randomly divided into three groups composed of
five animals each. The control, NC and stable
CXCR7shRNA transfected SMMC-7721 cells (1 × 10
6
for each) were inoculated subcutaneously into the back
of nude mice and tumor size was measured every 4
days. The tumor size was measured by a caliper, and
the tumor volume was calculated using the formula
(length × width
2) / 2 .T h em i c ew e r es a c r i f i c e d3 2d a y s
after inoculation. The tumors were weighed and fixed in
4% polyformaldehyde. The tumor sections were excised
for immunohistochemical analysis.
Tumors dissected from CXCR7shRNA transfected
cells were referred to as CXCR7shRNA tumors, while
tumors dissected from control and NC cells as control
tumors and NC tumors respectively.
Statistical analysis
Data are reported as means ± SD. The one-way
ANOVA was used for data analysis. All statistics were
calculated using SPSS 16.0 software (SPSS, Chicago, IL,
USA). P < 0.05 was considered as statistically significant.
Results
Expression of CXCR7 in hepatocellular carcinoma tissues
from patients
Little is known about the expression of CXCR7 in HCC.
To investigate whether CXCR7 might play a role in HCC
development, we first examined its expression in 35 hepa-
tocellular carcinoma tissues and 25 normal liver tissues
using immunohistochemist r y .T h ep o s i t i v er a t i oo f
CXCR7 was 91% (32 of 35 cases) in hepatocellular carci-
noma tissues. In most cases, the CXCR7 staining localized
to both the cytoplasm and the cell membrane but not in
the cellular nucleus (Fig. 1A). However, the positive ratio
of CXCR7 was only 10% (3 of 25 cases) in normal liver tis-
sues. Most of normal liver tissues displayed very low or
undetectable CXCR7 levels (Fig. 1B). Together, these data
demonstrated a significant increase of CXCR7 expression
level in hepatocellular carcinoma tissues.
Expression of CXCR7 on HCC cell lines and HUVECs
Initial evidence has indicated that CXCR7 is overex-
pressed in many human cancer cells [4,24,25]. To deter-
mine whether CXCR7 is also expressed in HCC cell
lines, we first evaluated the expression of CXCR7 by
RT-PCR in a panel of HCC cell lines (HepG2, Hep3B,
SMMC-7721, MHCC97L, MHCC97H and HCCLM6).
As shown in Fig. 2A, CXCR7 mRNA expression was
clearly detected in six HCC cell lines, with different
Figure 1 CXCR7 expression in human hepatocellular carcinoma tissues and normal liver tissues. Expression of CXCR7 was analyzed in 35
hepatocellular carcinoma and 25 normal liver tissues by immunohistochemistry. Representative pictures of histological sections of both
hepatocellular carcinoma (A) and normal liver tissues (B) stained with anti-CXCR7 antibody. Original magnification, 200×.
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sion of CXCR7 was the highest in MHCC97H and
HCCLM6 cells. In addition, most of the HCC cell lines
expressed both of the CXCR7 and CXCR4 (Fig. 2A).
Expression of CXCR7 mRNA was also tested in
HUVECs. We observed low levels of CXCR7 mRNA
expression in HUVECs (Fig. 2A).
To determine CXCR7 protein expression, Western
blot analysis was conducted on protein samples derived
from HUVECs and a panel of HCC cell lines. The
results of Western blot analysis are similar with RT-
PCR analysis. As shown in Fig. 2B and 2C, all HCC cell
lines expressed CXCR7. All low aggressive cell lines
(HepG2, Hep3B, SMMC-7721 and MHCC97L) had
lower levels of CXCR7. In HUVECs, CXCR7 was almost
undetectable. Of interest, the high aggressive cell lines
(MHCC97H and HCCLM6 cells)exhibited higher levels
of CXCR7 protein than did the low aggressive cell lines.
These results imply the potential involvement of CXCR7
in invasion of cancer cells.
The vector stably expressing CXCR7shRNA causes
effective and specific down-regulation of CXCR7
expression
In order to study the potential role of CXCR7 in HCC cell
lines, we used pGPU6/Neo-shCXCR7 directed at
nucleotides 223 to 243 of CXCR7 to selectively
reduce CXCR7 expression in the SMMC-7721cells.
CXCR7shRNA and scrambled shRNA were used to trans-
fect SMMC-7721 cells. After G418 selection, the knock-
down efficiencies were subsequently tested using RT-PCR
and Western blot. As shown in Fig. 3A, CXCR7 mRNA
levels were reduced by 85.0% in CXCR7 shRNA trans-
fected cells, compared with the control cells. Similar to
RT-PCR results, the expression level of CXCR7 protein
were reduced by 80.0% in CXCR7 shRNA transfected cells
(Fig. 3B). The scrambled sequence shRNA had no effect
on CXCR7 expression (Fig. 3B). These results demon-
strated that the expression of CXCR7 was specifically
silenced in SMMC-7721 cells.
CXCR7 silencing inhibits CXCL12 induced enhancement
on HCC cells invasion in vitro
The CXCL12/CXCR7 interaction was reported to regu-
late invasive and metastatic behavior of several tumors
[4,24]. It is therefore of interest to investigate the effect
of CXCR7 on HCC cells invasion by reducing CXCR7
expression using siRNA. To evaluate a role of CXCR7
in regulating the invasive ability of HCC cells, we
selected the SMMC-7721 cell line as a model. Cell inva-
sion experiments were performed with a Matrigel inva-
sion chamber, which is considered an in vitro model
Figure 2 Expression of CXCR4 and CXCR7 in HCC cell lines and HUVECs. A. RT-PCR was performed on various cell lines to determine CXCR7
and CXCR4 mRNA expression. GAPDH was used as a control. B. Western blot analysis was performed to detect CXCR7 and CXCR4 protein
expression. b-actin was used as a control to ensure equal loading. Data shown is representative of three independent experiments. C. The
intensity of protein bands was quantified and was shown as relative expression level after normalized by b-actin (n = 3, means ± SD).
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SMMC-7721 cells spontaneously invaded through artifi-
cial basement membrane in the absence of CXCL12. In
addition, we found that CXCL12 induced a significant
and dose-dependent increase of cancer cell invasion
through Matrigel. We next evaluated the effect of silen-
cing of CXCR7 on SMMC-7721 cells invasion. The
CXCR7shRNA cells displyed decreased invasive ability
compared with control cells and NC cells (Fig. 4C and
4D). Taken together, these findings indicate that
CXCL12 potently enhances the invasive ability of
SMMC-7721 cells and that silencing of CXCR7 inhibits
the invasive behavior of the cells induced by CXCL12.
CXCR7 silencing inhibits CXCL12 induced enhancement
on HCC cells adhesion in vitro
Tumor cell adhesion to the ExtraCellular Matrix (ECM)
is an important step of the invasion process. To analyze
the effect of CXCR7 expression on the adhesion of
tumor cells to LN or FN, HCC cells were examined by a
cell adhesion assay. As shown in Fig. 5, SMMC-7721
cells displayed an enhanced cell adhesion to LN or FN
in the presence of CXCL12. Adhesion of SMMC-7721
cells to LN was greater than adhesion to FN or BSA.
However, cells transfected by CXCR7shRNA showed
significantly reduced ability of adhesion to LN or FN
compared with the control and NC cells. Control, NC
and CXCR7shRNA transfected cells adhered equally to
BSA-coated dishes. Together, these results indicate that
treatment with CXCL12 increases adhesive ability of
SMMC-7721 cells and CXCR7s i l e n c i n gr e s u l t si n
decreased adhesive ability.
CXCR7 silencing inhibits tumor cell-induced tube
formation in vitro
To address whether CXCL12/CXCR7 interaction could
mediate in vitro tumor cell-induced tube formation, a
coculture system was used in which HUVECs were
induced by HCC cells to form capillary-like structures.
The tube formation of HUVECs on the Matrigel was
quantified by measuring the tube number. As shown in
Fig. 6, control and NC cells induced HUVECs to differ-
entiate into capillary-like structures within 24 h. In con-
trast, SMMC-7721 cells transfected with CXCR7shRNA
markedly inhibited tumor cell-induced tube formation.
HUVECs showed a significant 32% decrease in the num-
ber of tubes after transfecting SMMC-7721 with
CXCR7shRNA.
CXCL12 induces VEGF secretion through CXCR7
in HCC cells
To evaluate whether CXCL12 contributes to proangio-
genic factor secretion in HCC cells, we treated SMMC-
7721 cells with CXCL12 (100 ng/ml) and measured
secretion of proangiogenic factor VEGF by ELISA analy-
sis. As shown in Fig. 7, VEGF secretion increased signif-
icantly when SMMC-7721 cells were treated with
CXCL12 for 24 h. To further investigate whether VEGF
Figure 3 Downregulation of CXCR7 expression in SMMC-7721 cells by transfection with CXCR7shRNA. SMMC-7721 cells were stably
transfected with CXCR7shRNA. CXCR7 expression was strongly suppressed by specific CXCR7shRNA. A. cellular RNA was harvested after G418
selection and CXCR7 mRNA was measured using RT-PCR. GAPDH was used as a loading control. B. after G418 selection, the protein expression
levels of CXCR7 were measured by Western blot using anti-CXCR7 antibody and b-actin as a loading control. The experiment was repeated three
times with similar results.
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examined for their invasive ability after stimulation with different concentrations of CXCL12 (0, 10 or 100 ng/ml). Representative pictures are
shown. B. mean number of invasive cells from each group. Data are expressed as means ± SD. *p < 0.05 (as compared with untreated cells).
C. CXCR7shRNA transfected, NC and control cells were treated with CXCL12 (100 ng/ml). The invasive ability of CXCR7shRNA transfected cells
appeared significantly reduced, compared with control cells and NC cells. The pictures highlight the differences in number between the
CXCR7shRNA transfected, control and NC cells able to invade through Matrigel. D. mean number of invasive cells from five independent fields/
well is indicated. Data are expressed as means ± SD from three independent experiments. *p < 0.05 (as compared with control cells).
Figure 5 Effect of CXCR7 silencing on HCC cells adhesion in vitro. SMMC-7721 cells were treated as described in Materials and Methods.
SMMC-7721 cells displayed an enhanced cell adhesion to LN or FN in the presence of CXCL12. Cells transfected with CXCR7shRNA showed
significantly reduced ability of adhesion to LN or FN compared with control and NC cells. Each bar represents mean ± SD from three
independent experiments. *p < 0.05 (as compared with untransfected cells).
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Page 8 of 14secretion was mediated by CXCR7, CXCR7 expression
was inhibited by RNA interference before treatment
with CXCL12. Significant reduction in VEGF secretion
was observed in CXCR7shRNA cells compared with
control and NC cells. Thus, these findings indicate that
CXCL12 can induce VEGF secretion in SMMC-7721
cells and that CXCR7 can serve as a factor involved in
regulation of secretion of VEGF.
CXCR7 is up-regulated by VEGF stimulation and enhances
HCC cells invasion
Burns et al. [4] have shown that CXCR7 expression can
be up-regulated by TNF-a and IL-1b stimulation. To
explore whether expression of CXCR7 could be affected
by VEGF simulation, we first used PT-PCR analysis to
evaluate the effect of VEGF (50 ng/ml) on CXCR7
expression in HUVECs and SMMC-7721 cells. Interest-
ingly, we found that VEGF substantially increased
CXCR7 mRNA in a time-dependent manner (Fig. 8A).
In HUVECs, the CXCR7 mRNA increased as early as 8
h after VEGF treatment and showed further up-regula-
tion at 16 h and 24 h. VEGF treatment of SMMC-7721
cells also caused an increase in CXCR7 mRNA in a
time-dependent manner starting as early as 8 h.
We also tested CXCR7 protein expression with Wes-
tern blot analysis. Consistent with the RT-PCR results,
CXCR7 protein levels were time-dependently increased
after VEGF stimulation (Fig. 8B). In HUVECs, CXCR7
protein levels were changed at 8 h and significantly
increased at 16 h and 24 h following VEGF stimulation.
When SMMC-7721 cells were treated with VEGF,
CXCR7 protein levels increased starting at 8 h and
peaked at 24 h. Earlier studies have shown CXCR7 fre-
quently overexpressed on tumor blood vessels [4]. One
possible explanation might be that cytokines such as,
TNF-a,I L - 1 b and VEGF produced from tumor micro-
environment enhanced the expression of CXCR7.
To further evaluate whether the up-regulation of
CXCR7 expression by VEGF stimulation is functional,
Matrigel invasion assay was performed to analyze the
Figure 6 Effect of CXCR7 silencing on tube formation induced
by SMMC-7721 cells. HUVECs were cocultured with SMMC-7721
cells, as described in Materials and Methods. Inhibition of CXCR7
expression in SMMC-7721 cells impaired tube formation induced by
SMMC-7721 cells. Each bar represents mean ± SD from three
independent experiments. *p < 0.05 (as compared with control
cells).
Figure 7 CXCL12 induces VEGF secretion through CXCR7 in SMMC-7721 cells. SMMC-7721 cells were plated in the 24-well plates. SMMC-
7721 cells were serum starved for 24 h, and the cells were treated with CXCL12 (100 ng/ml). The cultured supernatants were harvested 24 h
after treatment, and VEGF was measured by ELISA assay. VEGF secretion of SMMC-7721 cells increased significantly after treatment with CXCL12
for 24 h. Cells transfected with CXCR7shRNA displayed decreased VEGF secretion compared with control and NC cells. Each bar represents mean
± SD from three independent experiments. *p < 0.05 (as compared with control cells).
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towards CXCL12. SMMC-7721 cells pretreated with
VEGF for 16 h were allowed to invade through a Matri-
gel-coated membrane towards CXCL12 for 24 h.
Although SMMC-7721 cells demonstrated invasive abil-
ity in response to CXCL12 in the abesence of VEGF, the
magnitude of these responses was significantly enhanced
in those cells pretreated with VEGF for 16 h (Fig. 8C
a n d8 D ) .T h e r e f o r e ,w eh a v ed e m o n s t r a t e dt h a tV E G F
treatment not only increases expression of CXCR7 on
SMMC-7721 cells but also enhances the invasive ability
of these cells in response to CXCL12.
Inhibition of tumor growth and angiogenesis
by silencing of CXCR7
The results of in vitro studies strongly suggested that
CXCR7 mediated invasion and angiogenesis. To investi-
gate whether CXCR7 plays a role in tumorigenesis, we
inhibited expression of CXCR7 by transfecting SMMC-
7721 cells with CXCR7shRNA. After G418 selection,
CXCR7shRNA, NC and control cells were inoculated
subcutaneously into the back of nude mice and tumor
size was measured every 4 days. Interestingly, tumor
growth was affected by knockdown of CXCR7 expres-
sion in SMMC-7721 cells. As shown in Fig. 9A, B and
9C, SMMC-7721 cells transfected with CXCR7shRNA
showed significantly reduced tumor growth compared
with control and NC cells. At the end of 32 days, con-
trol tumors grew to an average size of 1107.6 ± 128.3
mm
3 and 0.845 ± 0.057 g. CXCR7shRNA tumors grew
to 493.8 ± 49.6 mm
3 and 0.341 ± 0.039 g, showing
55.3% tumor growth inhibition which is statistically dif-
ferent from control tumors. No statistic differences were
obtained between NC tumors and control tumors. No
weight loss and decreased activity were observed in all
the mice (data not shown). Therefore, these results indi-
cate that silencing of CXCR7 substantially inhibited the
tumor growth.
The above data demonstrated that silencing of CXCR7
substantially suppressed tumor growth. One possible
mechanism for slower growth of CXCR7shRNA tumors
was the decreased angiogenesis. Therefore, we investi-
gated whether silencing of CXCR7 could result in sup-
pression of tumor angiogenesis. MVD was calculated by
averaging the CD31
+ microvessels of tumors in each
group. As shown in Fig. 9E, tumor vessels formation
Figure 8 Effect of VEGF stimulation on CXCR7 expression in HUVECs and SMMC-7721 cells. HUVECs and SMMC-7721 cells were stimulated
for 8, 16 and 24 h in the presence or absence of VEGF (50 ng/ml) respectively. A. total RNA was analyzed by RT-PCR for CXCR7 mRNA
expression. GAPDH was used as an internal control. B. HUVECs and SMMC-7721 cells were treated as in A and then subjected to Western blot
analysis to examine CXCR7 protein expression. b-actin was used as an internal control. Results are representative of three separate experiments.
C and D. SMMC-7721 cells pretreated or not with VEGF (50 ng/ml) were used for Matrigel invasion assay, adding CXCL12 (100 ng/ml) to the
bottom chamber. The number of invasive cells in five fields/well is reported. Data are expressed as means ± SD from three independent
experiments.*p < 0.05 (as compared with untreated cells).
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CXCR7 resulted in a significant reduction of MVD in
CXCR7shRNA tumors compared with those of control
and NC tumors (Fig. 9D). These results indicated that
silencing of CXCR7 substantially suppressed angiogen-
esis and subsequently inhibited the tumor growth.
To extend our in vitro findings and evaluate the con-
tribution of CXCR7 to metastasis formation in vivo,t h e
effect of CXCR7 silencing on organ metastasis was next
examined. We did not observe that HCC cells sponta-
neously metastasized to the lungs and other organs of
mice (data not shown). None of the mice developed
lung metastasis.
In summary, results from the heterotopic models
showed that silencing of CXCR7 inhibited the tumor
growth but not the metastasis of HCC cells in vivo.
Discussion
The identification of new biomarkers for the early detec-
tion of HCC is critical in the development of tumor-tar-
geted therapy, and would likely have an important
positive effect on the prognosis of this disease. CXCL12
plays a well-recognized role in the process of tumor
progression. Accumulating evidence indicates that
CXCL12 and its receptors are involved in cancer devel-
opment through the inhibition of apoptosis, and promo-
tion of angiogenesis, cellular proliferation, invasion and
metastasis [27,28]. CXCR7 expression has been reported
in various human cancers, including carcinomas of the
lung, prostate, pancreas and breast, as well as HCC
[4,23-25]. In the present study, we observed that human
hepatocellular carcinoma tissues exhibited increased
expression of CXCR7 as compared to normal liver tis-
sues. We also found that expression of CXCR7 is ele-
vated in all six HCC cell lines compared with HUVECs.
In addition, we observed that high metastatic potential
cell lines expressed significantly higher levels of CXCR7
than low metastatic potential cell lines. This finding
implies that CXCR7 overexpression may be involved in
invasion and metastasis nature of HCC.
Considerable efforts have been made in recent years to
elucidate the biological function of chemokine receptors
Figure 9 Effect of CXCR7 silencing on tumor growth. About 2 × 10
6 CXCR7shRNA, control and NC cells were inoculated subcutaneously into
the back of five different nude mice in each group. On day 32 after tumor inoculation, the mice were sacrificed. A. representative pictures from
each group of mice bearing tumors. B. tumor volume was measured at the indicated days. Data shown are means ± SD (n = 5). *p < 0.05 (as
compared with both control and NC tumors). C. weight of the tumor was determined after dissection at the end of the experiment. As shown,
both tumor volume and tumor weight were dramatically decreased as the consequence of CXCR7 silencing. Data shown are means ± SD
(n = 5). *p < 0.05 (as compared with both control and NC tumors). D. tumor sections were examined for MVD. Tumor vessels in a three
randomly selected fields were counted in tumor sections in each group. Data shown are means ± SD. *p < 0.05 (as compared with control and
NC tumors). E. inhibition of tumor angiogenesis by silencing CXCR7. Tumor sections were stained with anti-CD31 antibodies. Positive staining is
indicated by an arrow.
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CXCR7 in regulating HCC cells invasion is unclear. In
this study, we observed that treatment with CXCL12
enhanced invasion and silencing of CXCR7 significantly
inhibited the invasive ability of SMMC-7721 cells. Our
study indicated the significance of CXCR7 on HCC cells
invasion. These results are consistent with recent studies
showing that CXCR7 mediates chemotaxis of cancer
cells towards CXCL12 [24,26]. Some studies have shown
that CXCR7 can not trigger chemotaxis and activate cal-
cium mobilization and intracellular signaling cascades,
such as PI3K and ERK pathways [19,29]. However, a
recent study has demonstrated that CXCR7 is not a
decoy but a functional seven-transmembrane span che-
mokine receptor and can induce phosphorylation of
MAPK p42/44 and AKT in human rhabdomyosarcoma
cell lines [20]. In this study, we did not elucidate the
molecular mechanisms by which CXCR7 regulated the
invasion of HCC cells. Another recent study suggests
that signaling pathways mediated by CXCR7 are inde-
pendent of those triggered through CXCR4 [30]. There-
fore, it is reasonable to speculate that CXCR7 may exert
effects on other signaling. Also, the different biological
effects elicited by CXCR7 may depend on cell type.
Thus, further studies elucidating roles of CXCR7 in
invasion and signaling cascades activated by CXCL12/
CXCR7 axis are required.
Tumor cells interact with ECM components and base-
ment membranes, an essential initial event during the
process of invasion. It also has been reported that
expression of CXCR7 can regulate adhesion of tumor
cells to endothelial cells [19,24]. Our results demon-
strated that CXCL12 could induce adhesion of SMMC-
7721 cells to FN and LN. The enhanced cell-matrix
adhesion may contribute to metastasis of tumor cells. In
addition, we also found that RNAi-mediated down-regu-
lation of CXCR7 significantly inhibited CXCL12 induced
adhesion of SMMC-7721 cells to LN or FN. Therefore,
these findings clearly indicate that CXCR7 participate in
CXCL12 induced cell-matrix adhesion. Tumor metasta-
s i si sam u l t i s t e pp r o c e s st h a ti n v o l v e st h ec o o r d i n a t e d
events of invasion, adhesion, proteolysis and migration.
The decreased adhesive ability of HCC cells could lead
to inhibition of the invasion of SMMC-7721.
Cancer cells depend on angiogenesis to survive and
proliferate [31]. We observed that HCC cells could
induce in vitro tube formation, which could promote
tumor growth. Although CXCL12 induced VEGF secre-
tion has been reported in various cells, such as lympho-
hematopoietic cells and prostate cancer cells [32,33],
CXCL12 induced VEGF production in HCC cells has
not been previously studied. In the current study, we
found that CXCL12/CXCR7 interaction promoted secre-
tion of VEGF, a potent survival factor for endothelial
cells, and one of the most prominent angiogenic factors
produced by various tumor cells. Furthermore, our data
demonstrate that knockdown of CXCR7 inhibits secre-
tion of VEGF and tube formation, suggesting that
CXCR7 may be involved in the regulation of angiogen-
esis in HCC.
Initial evidence has indicated that expression levels of
CXCR7 are frequently high in tumor-associated
endothelial cells and activated endothelial cells, but not
in normal endothelial cells [4,19]. Our results also con-
firm that CXCR7 expresses in HUVECs with low levels.
To date, very little is known in regard to the regulation
of CXCR7 expression in cancer cells and normal cells.
In this study, we demonstrated that VEGF stimulation
enhanced CXCR7 mRNA and protein levels not only in
HCC cell lines but also in HUVECs. A large quantity of
VEGF is produced from tumor microenvironment,
which could result in enhanced expression of CXCR7 in
tumor-associated blood vessels. Further studies elucidat-
ing molecular mechanisms by which VEGF regulates
expression of CXCR7 are under way. Interestingly, we
also observed that invasive ability of SMMC-7721 cells
pretreated with VEGF was significantly enhanced. These
results clearly indicated that VEGF-induced expression
of CXCR7 in HCC cells was functional. Because VEGF
is a secreted mitogen and plays a key role in regulating
tumor angiogenesis [34], we can assume that under
pathological conditions such as cancer, CXCR7 may be
up-regulated by VEGF and that CXCR7, in turn, might
exert an angiogenic effect increasing VEGF production
through the CXCL12/CXCR7 axis.
Previous reports have demonstrated that CXCR7 plays
an important role in tumor growth [4,19,24]. However,
the data from Meijie et al. [29] have shown no effect of
CXCR7 on tumor growth and metastasis was observed.
One possible explanation might be that the different
effects of CXCR7 on tumor growth and metastasis may
be dependent on cell type. To further confirm our in
vitro findings, we have explored the role of CXCR7 in
tumor growth in SMMC-7721 xenograft mouse tumor
model. In the present study, RNAi-mediated inhibition
of CXCR7 partially suppressed HCC tumor growth in
nude mice. Tumor angiogenesis is essential for both
cancer growth and lethal metastatic cancer spread [35].
To investigate potential mechanisms underlying the
CXCR7 silencing-mediated reduction in tumor growth,
we examined the expression of gene (CD31) regulating
angiogenesis in the tumors of mice. We found that inhi-
bition of CXCR7 resulted in reduction in MVD. Thus, it
is reasonable to speculate that inhibition of angiogenesis
may lead to a significant delay in tumor growth. We did
not observe that cancer cells spontaneously metastasize
to other organs, such as lung, liver and spleen. Also,
tumor metastasis was not affected after knockdown of
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that SMMC-7721 cells are unable to metastasize to
other organs by subcutaneous tansplantation in mice.
Thus, we can not conclude that expression of CXCR7
do not affect tumor metastasis in vivo.O r t h o t o p i c
implantation of HCC cells should be used to further
evaluate the role of CXCR7 in regulating tumor
metastasis.
T h ea b o v ef i n d i n g si m p l yt h a tC X C L 1 2 / C X C R 7i n t e r -
action may regulate multiple processes in HCC invasion
and tumor growth. First, CXCR7 could affect CXCL12
induced tumor cell adhesion to ECM. Second, CXCR7
could regulate HCC invasive ability through angiogenesis
and VEGF secretion. Third, up-regulation of CXCR7
expression by VEGF stimulation could enhance the inva-
sive ability of cancer cells. Thus, we provide mechanistic
evidence that CXCL12/CXCR7 interaction may affect
HCC progression by multiple mechanisms including
adhesion, invasion, angiogenesis, VEGF production and
tumor growth. Because CXCR4 is also a receptor for
CXCL12, we can not exclude the possibility that CXCR4
may be involved in regulating these biological behaviors
triggered by CXCR7. Although our study shows the
importance of CXCR7 in HCC invasion, angiogenesis
and tumor growth, the role of CXCL12/CXCR7 interac-
tion in tumor progression are not fully established. More-
over, a recent study has shown that AMD3100, a small
synthetic inhibitor of CXCR4, not binds only to CXCR4,
but also to CXCR7 [31]. We propose that more attention
should be paid to CXCL12/CXCR4 axis and CXCL12/
CXCR7 axis. Thus, further studies elucidating the role of
CXCL12/CXCR7 axis in cancer development is needed.
Conclusions
In summary, CXCR7 was highly expressed in hepatocel-
lular carcinoma tissues. We presented the first evidence
that suppression of CXCR7 expression by RNA interfer-
ence impairs in vitro cellular invasion, adhesion, VEGF
secretion and angiogenesis. We also observed that
knockdown of CXCR7 significantly inhibited tumor
growth but not metastasis in vivo.M o r e o v e r ,w ef o u n d
that VEGF stimulation up-regulated the expression of
CXCR7 in SMMC-7721 cells and HUVECs. Taken
together, this study provides novel evidence that inhibi-
tion of CXCR7 expression may be an effective approach
to suppressing tumor growth of HCC.
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